SCHEMBL3676189

SCHEMBL3676189

CN1CCN(c2cncc3occc23)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.38
LATS1 O95835 1/20 0.38
ADRA2C P18825 2/20 0.38
ADRA2A P08913 1/20 0.36
NCF1 P14598 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
DRD2 P14416 3/20 0.36
DRD3 P35462 3/20 0.36
HRH4 Q9H3N8 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36
HTR2A P28223 1/20 0.36
METAP1 P53582 1/20 0.35
CDK8 P49336 1/20 0.35
MET P08581 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3086515 0.78 HTR2C (0.49) NCF1
SCHEMBL3600354 0.77 DRD2 (0.49) ADRA2CKMT2ADRD2DRD3DRD4
SCHEMBL28033595 0.72 CYP11B1 (0.61) NCF1HRH4CDK8
SCHEMBL18475869 0.70 HTR6 (0.43) CYP3A4LATS1ADRA2CDRD2DRD3
SCHEMBL3679735 0.69 HTR2C (0.69) DRD2DRD3HRH4HTR2A
SCHEMBL14437993 0.67 DRD1 (0.32) DRD1HTR2A
SCHEMBL27290485 0.67 ADRA2C (0.47) CYP3A4LATS1ADRA2CADRA2AMEN1
SCHEMBL3588307 0.67 ALDH1A1 (0.53) ADRA2CNCF1DRD2DRD3HRH4
SCHEMBL2222784 0.66 ADRA2C (0.50) CYP3A4ADRA2CNCF1KMT2AHRH4
SCHEMBL12445165 0.65 MAPT (0.37) ADRA2CNCF1KMT2ADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799775-B2 such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-09-21 US claimed
EP-1724267-B1 PYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2013-11-06 EP disclosed
US-7799775-B2 such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-09-21 US disclosed
US-20070197551-A1 Pyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US disclosed
EP-1724267-A1 PYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197551-A1 Pyrimidine derivatives HTR3B, HTR3A, HTR1A CYP3A4 2803/4885LATS1 850/4885ADRA2C 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.